GV is a Mountain View-based venture capital firm that operates independently within Alphabet. It is one of the largest and most established multi-stage technology investors, with broad activity across software, healthcare, life sciences, and frontier science. The firm is known for combining deep technical diligence with the ability to support companies from early stage through scale.

In neurotech, GV has been a highly visible backer of brain-computer interface and neurodiagnostic companies, including Neuralink and Beacon Biosignals. More broadly, its life sciences strategy spans computational biology, AI-enabled healthcare, and advanced therapeutic platforms. GV’s strength lies in supporting technically demanding companies that sit at the convergence of hardware, software, AI, and biology.

GV invests globally, with a strong concentration in the United States and major presence in Europe. For neurotech founders, it is particularly relevant where the company combines machine learning, neurodata, sensing, or platform technologies with long-term clinical or computational potential. It is one of the clearest fits for ambitious neurotech companies building durable technical moats.